1. Home
  2. NRIX vs AHH Comparison

NRIX vs AHH Comparison

Compare NRIX & AHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • AHH
  • Stock Information
  • Founded
  • NRIX 2009
  • AHH 1979
  • Country
  • NRIX United States
  • AHH United States
  • Employees
  • NRIX N/A
  • AHH N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • AHH Real Estate
  • Sector
  • NRIX Health Care
  • AHH Finance
  • Exchange
  • NRIX Nasdaq
  • AHH Nasdaq
  • Market Cap
  • NRIX 728.6M
  • AHH 600.4M
  • IPO Year
  • NRIX 2020
  • AHH 2013
  • Fundamental
  • Price
  • NRIX $8.97
  • AHH $7.56
  • Analyst Decision
  • NRIX Strong Buy
  • AHH Buy
  • Analyst Count
  • NRIX 14
  • AHH 4
  • Target Price
  • NRIX $29.07
  • AHH $8.38
  • AVG Volume (30 Days)
  • NRIX 847.4K
  • AHH 500.8K
  • Earning Date
  • NRIX 10-10-2025
  • AHH 11-03-2025
  • Dividend Yield
  • NRIX N/A
  • AHH 10.95%
  • EPS Growth
  • NRIX N/A
  • AHH N/A
  • EPS
  • NRIX N/A
  • AHH 0.13
  • Revenue
  • NRIX $88,381,000.00
  • AHH $544,168,000.00
  • Revenue This Year
  • NRIX $74.59
  • AHH N/A
  • Revenue Next Year
  • NRIX N/A
  • AHH $2.61
  • P/E Ratio
  • NRIX N/A
  • AHH $57.86
  • Revenue Growth
  • NRIX 41.86
  • AHH N/A
  • 52 Week Low
  • NRIX $8.18
  • AHH $6.10
  • 52 Week High
  • NRIX $29.56
  • AHH $12.28
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 42.73
  • AHH 66.47
  • Support Level
  • NRIX $8.33
  • AHH $7.36
  • Resistance Level
  • NRIX $10.13
  • AHH $7.71
  • Average True Range (ATR)
  • NRIX 0.49
  • AHH 0.14
  • MACD
  • NRIX -0.00
  • AHH 0.03
  • Stochastic Oscillator
  • NRIX 35.56
  • AHH 77.27

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

Share on Social Networks: